GAITHERSBURG, Md.--(BUSINESS WIRE)--Gene Logic Inc. (NASDAQ:GLGC) announced today that Bethany Mancilla has been promoted to Senior Vice President, Business Development, to lead the Company’s partnering and licensing efforts. Since July 2004, Ms. Mancilla has been integral to the formation and development of Gene Logic’s Drug Repositioning partnerships with pharmaceutical companies including Pfizer, Roche, Abbott, Merck-Serono, Organon, and Solvay. She is also leading the Company’s efforts to secure a development partner for its proprietary drug candidate, GL1001. This compound is a clinical-stage drug candidate for which Gene Logic discovered a new potential therapeutic use to treat inflammatory bowel disease (IBD). GL1001 has shown indications of efficacy at relevant doses in in vivo testing for IBD.
